Protocol Reference
Retatrutide (LY3437943)
Retatrutide — phase 2 trial protocol as published
Summarise the escalation and maintenance structure reported in the published phase 2 obesity trial.
Clinical TrialsReviewed September 1, 2026
No established human dosing protocol exists for this compound. What follows describes the research context only — the conditions under which the compound has been studied, usually in animals or in vitro.
Research Context
- Source of this information
- Retatrutide is investigational. The only defensible protocol information comes from registered clinical trials. Nothing here describes clinical practice, because there is none.
- Evidence level
- Grade B — published phase 2 randomised trial; phase 3 ongoing at last review
- Population studied
- 338 adults with obesity, or overweight with at least one weight-related condition, without diabetes.
- Duration studied
- 48 weeks of treatment in the published phase 2 analysis.
- Route reported
- Subcutaneous injection, once weekly (trial setting)
Protocol as Reported
- 01The published trial randomised participants to placebo or one of several retatrutide dose groups, with stepwise escalation from low starting doses to assigned maintenance levels.
- 02Escalation intervals were protocol-defined rather than participant-directed, with maintenance doses reached over several months.
- 03Study visits included regular safety laboratory assessment, heart rate monitoring and adverse event review.
Adverse Events Reported
- Gastrointestinal events were dose-related and most common during escalation.
- Dose-dependent heart rate increases were reported.
- No long-term or post-marketing safety information exists.
Limitations
- No established human dosing protocol exists outside clinical trials, and no approved label defines one.
- Phase 2 evidence in a modest sample over under a year.
- Community protocols circulating online are not clinical standards and are not derived from the trial protocol.
Sources
- Phase 2 trial2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine - Regulatory document
Registered retatrutide trials
Educational reference only. Peptide Atlas does not provide medical advice or individualised dosing guidance, and nothing on this page should be used to guide personal use.